TABLE 2

The Effects of Monotherapy or Polytherapy on BMD

Region	Therapy	n	Mean	SD	95% CI
Lumbar spine	Polytherapy	52	0.933	0.188	0.881–0.985
	Carbamazepine monotherapy	33	0.848^*	0.213	0.772–0.924
	Valproate monotherapy	22	0.917	0.231	0.814–1.019
	Control	38	1.0289	0.131	0.986–1.072
Ward triangle	Polytherapy	52	0.792	0.307	0.706–0.877
	Carbamazepine monotherapy	33	0.744	0.394	0.604–0.884
	Valproate monotherapy	22	0.781	0.407	0.601–0.962
	Control	38	0.873	0.254	0.79–0.957
Greater trochanter	Polytherapy	52	0.708	0.140	0.669–0.747
	Carbamazepine monotherapy	33	0.656	0.134	0.608–0.703
	Valproate monotherapy	22	0.731	0.133	0.671–0.79
	Control	38	0.729	0.119	0.69–0.769
Femoral neck	Polytherapy	52	0.938	0.1507	0.896–0.98
	Carbamazepine monotherapy	33	0.887**	0.174	0.825–0.949
	Valproate monotherapy	22	0.974	0.163	0.901–1.046
	Control	38	1.004	0.102	0.971–1.038
Total hip	Polytherapy	52	0.813	0.161	0.768–0.857
	Carbamazepine monotherapy	33	0.762	0.213	0.686–0.838
	Valproate monotherapy	22	0.828	0.217	0.732–0.925
	Control	38	0.869	0.141	0.823–0.915

↵* P < 0.01 compared with control.
CI = confidence interval.